Candidate Pharmacogenomic and HLA Risk Alleles for Drug-Induced Liver Injury in Vietnamese Cancer Patients: A Pre-Specified Case-Control Study
This pre-specified case-control study of 101 Vietnamese cancer patients with drug-induced liver injury and 101 matched controls found no significant associations between DILI and candidate pharmacogenomic variants, HLA alleles, or CPIC actionable-allele burdens, suggesting that larger collaborative studies are required to detect moderate genetic risk factors in this population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When powerful medicines are used to fight cancer, they can sometimes cause a serious side effect: damage to the liver. This condition, known as drug-induced liver injury, can force doctors to stop a life-saving treatment or lead to severe health complications. For decades, scientists have wondered why some patients develop this injury while others, taking the exact same drugs, remain perfectly fine. The leading theory is that a person's genetic code holds the answer. Just as some people inherit blue eyes or a specific blood type, they may also inherit genetic variations that make their livers unusually sensitive to certain medications. Researchers have already found specific genetic markers that predict reactions to a few drugs, but these discoveries have mostly come from studies of European or East Asian populations. For the diverse populations of Southeast Asia, including Vietnam, this crucial genetic map has remained largely blank, leaving doctors without a clear way to predict who is at risk before starting treatment.
To fill this gap, a team of researchers in Vietnam conducted a careful study to see if they could find these genetic warning signs in their own patients. They focused on 101 cancer patients who had developed liver injury after receiving chemotherapy, targeted therapies, or immunotherapies. To ensure a fair comparison, they matched each of these patients with another person of the same age, sex, and cancer type who had taken the same drugs but suffered no liver damage. The researchers then examined the DNA of all 202 individuals, looking for specific genetic variations that might explain the difference. They checked hundreds of known candidate genes, searched for patterns in the immune system's genetic markers, and even looked at the entire genome for any hidden signals. They also specifically tested a genetic link that had been reported in a previous study involving a different Asian population, hoping to confirm if it held true for Vietnamese patients.
The results were clear and definitive: the researchers found no evidence that any of the genetic factors they tested were responsible for the liver injuries in this group. None of the 90 candidate gene variations showed a connection to the injury, and the specific immune system markers that cause reactions in other parts of the world did not appear to play a role here. Even the genetic link they tried to replicate from the previous study failed to show up in their data. The study also looked at a collection of genetic variations that are known to affect how the body processes drugs, but found that carrying these variations did not increase the risk of liver damage in this specific context. The researchers concluded that if such genetic risks exist for Vietnamese cancer patients, they are likely too subtle or too rare to be detected with a group of this size.
This does not mean that genetics plays no role, but rather that the specific genetic clues found in other parts of the world do not seem to apply here, or that the effects are too small to spot without a much larger group of people. The study highlights a critical reality in medical science: genetic risks are often specific to a population's unique history and ancestry. What works as a predictor in one country may not work in another. The researchers noted that their study was designed to find large, obvious genetic effects, much like looking for a bright light in a dark room. If the genetic causes of liver injury in Vietnam are more like faint glimmers, this study would not have been able to see them. Consequently, the findings suggest that doctors in Vietnam cannot yet use a standard genetic test to predict liver injury risk for cancer patients based on the genes currently known to science.
The team also observed that the liver injuries in their patients looked different from those seen in Western medical records. While Western cases often involve a mix of liver cell damage and bile flow blockage, the Vietnamese patients in this study almost exclusively showed damage to the liver cells themselves. This difference in how the injury appears might explain why the genetic markers found in Western studies did not match up. It suggests that the biological pathways leading to liver injury might vary across different regions, requiring local research to uncover the true causes. The study serves as a necessary step, proving that what works elsewhere cannot simply be copied and pasted into a new setting.
Ultimately, this research provides a solid foundation for future work by clearly defining what has been ruled out. It tells the medical community that for now, there is no simple genetic test available to screen Vietnamese cancer patients for liver injury risk using the genes currently known to science. The path forward requires larger studies involving many more patients to find the smaller, more complex genetic factors that might be at play. Until then, doctors must rely on careful monitoring of liver function during treatment rather than genetic prediction. The work underscores the importance of conducting research within the specific populations it aims to help, ensuring that medical advances are built on data that truly reflects the people they are meant to serve.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.